Rheumatoid arthritis: developing pharmacological therapies. - Wikidata - wikimedia - TriplyDB

Rheumatoid arthritis: developing pharmacological therapies.

Rheumatoid arthritis: developing pharmacological therapies.

http://www.wikidata.org/entity/Q34706975

about

Potential new drugs for therapy of chronic obstructive pulmonary disease.Ontology-based systematic representation and analysis of traditional Chinese drugs against rheumatism.

P2860

Q35164728-2C875A1C-09A6-4C57-AB10-D9AED9626BF6 Q48503272-34F8F895-B0F0-4FC2-8BF2-F519B14F76E3

P2860

Rheumatoid arthritis: developing pharmacological therapies.

http://www.wikidata.org/entity/Q34706975

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Rheumatoid arthritis: developing pharmacological therapies.

@ast

Rheumatoid arthritis: developing pharmacological therapies.

@en

Rheumatoid arthritis: developing pharmacological therapies.

@nl

type

label

Rheumatoid arthritis: developing pharmacological therapies.

@ast

Rheumatoid arthritis: developing pharmacological therapies.

@en

Rheumatoid arthritis: developing pharmacological therapies.

@nl

prefLabel

Rheumatoid arthritis: developing pharmacological therapies.

@ast

Rheumatoid arthritis: developing pharmacological therapies.

@en

Rheumatoid arthritis: developing pharmacological therapies.

@nl

P1433

Q34706975-A9438E6D-B8D8-4945-8D18-DCD70711FF64

P1476

Q34706975-46E7D62D-D619-412B-8BEB-4501D47FB17F

P2093

Q34706975-1326C2E9-864E-42C2-AD59-D9500E4E9F7C

Q34706975-74659161-D2B1-476C-B9DC-B7F85092AE52

P2860

Q34706975-01C8C3BA-0B87-41F6-9610-343D1E8B5D36

Q34706975-10E8FE0B-68CD-44A8-BAD7-AE11658954DB

Q34706975-134C6B41-DB34-4188-807B-5047DB497290

Q34706975-26F113B5-B5CE-44B6-9080-DB6DE2CAA75B

Q34706975-2AF7256C-AA0D-434F-8977-C008C966F668

Q34706975-3BB689EC-8646-402D-9953-0660FE658847

Q34706975-400466A8-D510-487F-8E54-12F157008EBD

Q34706975-45543A23-198D-4E67-976B-E9E1BB9D2E83

Q34706975-4556D29B-29CA-4F0C-B022-824EBD6620C7

Q34706975-50954A54-9E5D-4038-AFD2-7BFFEAB3547E

P304

Q34706975-1EDA83B2-39C6-4351-A781-72EBA0BC9431

P31

Q34706975-FD4AA7A2-73D1-4712-9154-9B346B582F97

P356

Q34706975-F1399D8F-7A60-43AA-A990-A2EF3EDC5F30

P407

Q34706975-59563997-B7C8-4DCD-B030-6C9619741909

P433

Q34706975-C5411FCB-9738-4AD3-8937-C16C4AA7DA73

P478

Q34706975-253235A1-56C1-4DE6-9B8C-2AEBE6520BA5

P577

Q34706975-EC47E7E3-5479-499C-A763-929F2A4F77B5

P698

Q34706975-0083BA5F-ED26-4484-BD31-FCA734CEED39

P356

13543784.11.7.927

P1433

Expert Opinion on Investigational Drugs

P1476

Rheumatoid arthritis: developing pharmacological therapies.

@en

P2093

Larry W Moreland

http://www.w3.org/2001/XMLSchema#string

Richard J Misischia

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.

P304

927-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.11.7.927

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12084003

http://www.w3.org/2001/XMLSchema#string